BioNTech SE (BNTX)
BioNTech SE Statistics
Share Statistics
BioNTech SE has 240.39M shares outstanding. The number of shares has increased by 0.94% in one year.
| Shares Outstanding | 240.39M |
| Shares Change (YoY) | 0.94% |
| Shares Change (QoQ) | 0.1% |
| Owned by Institutions (%) | 21.17% |
| Shares Floating | 236.63M |
| Failed to Deliver (FTD) Shares | 4.08K |
| FTD / Avg. Volume | 0.38% |
Short Selling Information
The latest short interest is 4.34M, so 1.81% of the outstanding shares have been sold short.
| Short Interest | 4.34M |
| Short % of Shares Out | 1.81% |
| Short % of Float | 4.7% |
| Short Ratio (days to cover) | 3.69 |
Valuation Ratios
The PE ratio is -39.73 and the forward PE ratio is -29.59. BioNTech SE's PEG ratio is 0.23.
| PE Ratio | -39.73 |
| Forward PE | -29.59 |
| PS Ratio | 9.61 |
| Forward PS | 6.5 |
| PB Ratio | 1.36 |
| P/FCF Ratio | -108.05 |
| PEG Ratio | 0.23 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for BioNTech SE.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.45, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.45 |
| Quick Ratio | 7.34 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.69 |
| Debt / FCF | -1.04 |
| Interest Coverage | -104.31 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $406.25K |
| Profits Per Employee | $-98.24K |
| Employee Count | 6,772 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 1.91 |
Taxes
| Income Tax | -12.4M |
| Effective Tax Rate | 1.83% |
Stock Price Statistics
The stock price has increased by 15.79% in the last 52 weeks. The beta is 1.08, so BioNTech SE's price volatility has been higher than the market average.
| Beta | 1.08 |
| 52-Week Price Change | 15.79% |
| 50-Day Moving Average | 102.37 |
| 200-Day Moving Average | 106.25 |
| Relative Strength Index (RSI) | 52.47 |
| Average Volume (20 Days) | 1.08M |
Income Statement
In the last 12 months, BioNTech SE had revenue of 2.75B and earned -665.3M in profits. Earnings per share was -2.77.
| Revenue | 2.75B |
| Gross Profit | 2.21B |
| Operating Income | -1.31B |
| Net Income | -665.3M |
| EBITDA | -367.1M |
| EBIT | -665.1M |
| Earnings Per Share (EPS) | -2.77 |
Balance Sheet
The company has 9.76B in cash and 254.2M in debt, giving a net cash position of 9.51B.
| Cash & Cash Equivalents | 9.76B |
| Total Debt | 254.2M |
| Net Cash | 9.51B |
| Retained Earnings | 19.1B |
| Total Assets | 22.53B |
| Working Capital | 16.28B |
Cash Flow
In the last 12 months, operating cash flow was 207.7M and capital expenditures -452.3M, giving a free cash flow of -244.6M.
| Operating Cash Flow | 207.7M |
| Capital Expenditures | -452.3M |
| Free Cash Flow | -244.6M |
| FCF Per Share | -1.02 |
Margins
Gross margin is 80.32%, with operating and profit margins of -47.77% and -24.18%.
| Gross Margin | 80.32% |
| Operating Margin | -47.77% |
| Pretax Margin | -24.63% |
| Profit Margin | -24.18% |
| EBITDA Margin | -13.34% |
| EBIT Margin | -47.77% |
| FCF Margin | -8.89% |
Dividends & Yields
BNTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BNTX is $144, which is 38.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $144 |
| Price Target Difference | 38.3% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
Scores
| Altman Z-Score | 6.93 |
| Piotroski F-Score | 2 |